home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2798.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
36 lines
Document 2798
DOCN M94A2798
TI Evaluation of long term oral administration of glycyrrhizin in
asymptomatic HIV-1 carrier.
DT 9412
AU Kinoshita S; Tsujino G; Yoshioka K; Akatani K; Imai M; Ikegami N; Osaka
National Hospital, Japan.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0317). Unique
Identifier : AIDSLINE ICA10/94369777
AB OBJECTIVE: The study was aimed at evaluating clinically and
immunologically the effectiveness of long-term oral administration of
glycyrrhizin (GL) to asymptomatic HIV-1 carrier (AC) to delay or prevent
the disease progression. METHODS: Daily dose of 150-225 mg of GL was
given to AC hemophiliac patients since 1987 in the first group, and
since 1989-1990 in the second group. CD4+ and CD8+ T cell counts in
blood samples and p24 antigens (Ag) in sera were monitored. RESULTS:
When GL was given to AC patients at a stage of their CD4+ cell counts >
500/ul, their CD4+ counts have been maintained > 500/ul up to now. When
GL was given to patients at a stage of the CD4+ counts between 200-500
per ul, their CD4 counts have been maintained > 200/ul. P24 Ag was not
detected in their sera throughout the period. CONCLUSION: Long-term oral
administration of GL from an early stage of asymptomatic HIV-1 carriers
is effective to maintain their AC stages without any side effects and
disease development for a long time.
DE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL Adjuvants,
Immunologic/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Administration,
Oral Carrier State/*DRUG THERAPY Cohort Studies Glycyrrhetinic
Acid/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
Hemophilia/COMPLICATIONS Human HIV Core Protein p24/BLOOD HIV
Infections/COMPLICATIONS/*DRUG THERAPY *HIV-1 Leukocyte Count T4
Lymphocytes CLINICAL TRIAL MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).